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ABSTRACT
Background: Amlodipine is a calcium channel blocker prescribed for the 
management of angina and hypertension. As a racemic mixture, amlodipine contains 
(R)- and (S)-amlodipine isomers, but only (S)-amlodipine as the active moiety pos-
sesses therapeutic activity. Based on pharmacologic research, it remains uncertain if 
(S)-amlodipine alone has similar efficacy and fewer associated adverse events (AEs) 
compared with the racemic mixtures. 
Objective: The aim of this systematic review and meta-analysis was to deter-
mine the effectiveness and tolerability of (S)-amlodipine compared with that of race-
mic amlodipine.
Methods: A systematic literature search was performed using MEDLINE 
(1966–2009), EMBASE (1966–2009), the Cochrane Central Register of Controlled 
Trials (issue 3, 2009), the Chinese Biomedical Database (1978–2009), and the China 
National Knowledge Internet (1980–2009). All randomized controlled trials (RCTs) 
comparing (S)-amlodipine 2.5 mg and racemic amlodipine 5.0 mg in the treatment of 
hypertension were included in the review. The outcome measures to be collected were 
cardiovascular events, systolic blood pressure (SBP), diastolic BP (DBP), and AEs. Qual-
ity assessments of clinical trials were conducted using a modified Jadad Scale, with trials 
being rated as low quality (score 0–3) or high quality (score 4–7). Meta-analysis of the 
included studies was performed using RevMan software.
Results: Of the 229 references identified, 214 were excluded after screening 
the titles, abstracts, or full texts. Fifteen RCTs were included, of which 13 were in 
Chinese and 2 in English. Based on the Jadad Scale score, 3 of the RCTs were classified 
as high quality (score 5 or 6) and the remaining 12 as low quality (score 1–3). None 
of the trials evaluated cardiovascular events beyond 40 weeks. Meta-analysis of the 
15 trials indicated that (S)-amlodipine was not significantly different from race- 
mic amlodipine in the effect on BP. When only high-quality studies were included, 
after 4 weeks’ treatment, the weighted mean difference (WMD) of SBP and DBP 
decrease (1 study) was –2.84 (95% CI, –6.42 to 0.74) with (S)-amlodipine and –1.71 
(95% CI, –3.48 to 0.06) with racemic amlodipine. After 8 weeks’ treatment, the 
WMD of SBP and DBP decrease (2 studies) was –1.13 (95% CI, –5.29 to 3.03) 
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and –1.34 (95% CI, –2.67 to –0.01), respectively. The risk difference (RD) for the 
number of patients who experienced AEs with (S)-amlodipine and racemic amlodipine 
was found to be –0.04 (95% CI, –0.06 to –0.02). When all the trials were included, 
(S)-amlodipine treatment was associated with significantly less edema than racemic 
amlodipine (RD, –0.02; 95% CI, –0.03 to 0.00); however, when only high-quality 
studies (2 studies) were included, no difference was found between the 2 groups (RD, 
0.01; 95% CI, –0.02 to 0.03). One high-quality study found significant differences 
in increases in aspartate and alanine aminotransferase activities in the 2 groups (RD, 
0.08; 95% CI, 0.01 to 0.05). No significant differences between the 2 groups were 
found in the incidence of headache (RD, 0.00; 95% CI, –0.02 to 0.01) or flushing 
(RD, –0.01; 95% CI, –0.02 to 0.00).
Conclusions: The majority of the clinical trials comparing (S)-amlodipine 
and racemic amlodipine treatment were low quality (12/15 [80%]). According to the 
limited evidence, there were no significant differences between (S)-amlodipine 2.5 mg 
and racemic amlodipine 5.0 mg in controlling BP. When all the trials were consid-
ered, (S)-amlodipine treatment was associated with significantly less edema than 
racemic amlodipine; however, when only high-quality trials were included, no signif-
icant difference was found. More long-term, high-quality RCTs with cardiovascu- 
lar events as the primary outcome are needed to compare the safety and efficacy of 
(S)-amlodipine and racemic amlodipine. (Curr Ther Res Clin Exp. 2010;71:1–29) 
© 2010 Excerpta Medica Inc.
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INTRODUCTION
Amlodipine, a third-generation dihydropyridine calcium channel blocker, is pre-
scribed for the management of angina and hypertension. In addition to the high de-
gree of specificity for vascular smooth muscle that racemic amlodipine shares with the 
other dihydropyridine drugs, racemic amlodipine also has unique pharmacokinetic 
characteristics (eg, slow time-to-effect and a long t1/2). As a result, racemic amlodipine 
has become one of the most commonly used antihypertensive agents in China and 
other countries.1
Adverse events (AEs) commonly associated with racemic amlodipine include ede-
ma, flushing, dizziness, and headache, which are usually not serious but can affect the 
patient’s daily life and performance at work, leading to noncompliance with the 
treatment regimen.2 As a racemic mixture, racemic amlodipine contains (R)- and 
(S)-amlodipine isomers in a 1:1 ratio, but only (S)-amlodipine as the active moiety 
possesses therapeutic activity.3 Therefore, a racemic amlodipine formulation com-
posed of only (S)-amlodipine was developed. The standard dose of (S)-amlodipine is 
half that of racemic amlodipine.
Although (S)-amlodipine has been marketed in some countries and clinical trials have 
been conducted comparing the 2 drugs, a systematic review of the trials has not been done. 
Therefore, we conducted this systematic review and meta-analysis to determine the effec-
tiveness and tolerability of (S)-amlodipine compared with racemic amlodipine.
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METHODS
Search Strategy
A computer-aided systematic search of MEDLINE (1966–2009), EMBASE 
(1966–2009), the Cochrane Central Register of Controlled Trials (issue 3, 2009), the 
Chinese Biomedical Database (1978–2009), and the China National Knowledge In-
ternet (1980–2009) was conducted in August 2009 using combinations of the follow-
ing search terms: (S)-amlodipine, levoamlodipine, amlodipine isomer, amlodipine enantiomer, 
and chiral switch of amlodipine. The bibliographies of the extracted articles were re-
viewed to find other related randomized controlled trials (RCTs). Google academic 
searching was used to find meeting abstracts. The Web site www.clinicaltrials.gov was 
searched, and we requested that Pfizer Pharmaceuticals Ltd. and Jilin Tianfeng Phar-
maceutical Co., Ltd., provide data from unpublished trials.
Inclusion and Exclusion Criteria
All RCTs of (S)-amlodipine compared with racemic amlodipine for the treatment 
of hypertension were included. In the trials, the standard doses were (S)-amlodipine 
2.5 mg and racemic amlodipine 5.0 mg. Male and female patients aged 18 to 75 years 
diagnosed as having mild to moderate primary hypertension were included. The pri-
mary outcome measures to be collected included mortality, stroke, coronary heart 
disease, and cardiovascular events. The secondary outcome measures included blood 
pressure (BP), heart rate, and AEs occurring during treatment.
Publications meeting any of the following criteria were excluded: reviews, case 
reports, and experimental studies; studies using drugs other than racemic amlodipine 
as control; studies having factors other than (S)-amlodipine and racemic amlodipine 
that might affect findings in the treatment groups; repeated publication of the results 
of the same study; and having a nonrandomized controlled trial design. 
Quality Assessment and Data Collection
Each potentially eligible study was independently assessed by 2 qualified reviewers 
(F.L. and M.Q.) to determine whether it met the inclusion criteria and to assess its 
methodologic quality. A modified Jadad Scale4 that added allocation concealment as 
a criterion was used to assess methodologic quality. The Jadad Scale criteria were as 
follows: sequence generation—appropriate = 2 points, unclear = 1 point, and inap-
propriate = 0 points; allocation concealment—appropriate = 2 points, unclear = 
1 point, and inappropriate = 0 points; blinding method—appropriate = 2 points, 
unclear = 1 point, and inappropriate = 0 points; withdrawal and exit—described = 
1 point and not described = 0 points. A total score was computed by summing the 
scores given for all the criteria (range, 0–7 points). Low quality was defined as a score 
of 0 to 3 points and high quality as 4 to 7 points. 
The 2 reviewers independently extracted data from each included study using a 
standardized form and assessed the quality of the studies. Conflict between the review-
ers was resolved through discussion, and if consensus could not be reached, the third re-
viewer (S.-D.Z.) determined the outcome. The characteristics of each study were identified 
and extracted, including methodology, number of cases, participant characteristics (eg, 
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age, sex, and ethnicity), detailed experimental and control interventions, and primary and 
secondary outcomes. The original investigators were contacted to obtain missing informa-
tion, and the unclear data were not used until the investigators replied. 
Statistical Analysis
RevMan version 5.0 (Cochrane Collaboration, Copenhagen, Denmark) was used to 
combine results from ≥2 separate trials. Before the results of the studies were com-
bined, statistical heterogeneity was identified and measured using the χ2 test (P =
0.05). When heterogeneity was identified in a group of trials (P < 0.05), random- 
effects models were applied. Otherwise, fixed-effects models were used and CIs of 
pooled effects were calculated. Odds ratio and risk difference (RD) were calculated for 
dichotomous outcomes, while the weighted mean difference (WMD) was used for 
continuous outcomes measured using the same methodology. The range of the RD or 
WMD was expressed as 95% CI. P < 0.05 was considered statistically significant. 
Subgroup analysis was performed to answer specific questions about particular patient 
groups or types of interventions.
Using the RevMan software, a funnel plot was made to identify potential publica-
tion bias. 
RESULTS
No unpublished studies were provided by the manufacturers. No meeting abstracts in 
English or other languages were found in a Google academic search. An RCT titled 
Efficacy and Safety Study of S-Amlodipine Gentisate Compared to Amlodipine Besylate to 
Treat Mild-to-Moderate Hypertension was found at www.clinicaltrials.gov, but the results 
were not provided; therefore, the trial was not included here. A total of 229 references 
were identified, and 15 RCTs were included (Figure 1). All 15 studies used a dose of 
2.5 mg of (S)-amlodipine and 5.0 mg of racemic amlodipine. The characteristics of 
the included trials are listed in Table I.5–19
Quality Assessments
Twelve studies, in which the description of the randomization process was not 
given, allocation concealment was not done, blinding was not used, or follow-up was 
not conducted, were classified as low quality (modified Jadad score 1–3).5–7,9–12,14–17,19
Three trials were classified as high quality (modified Jadad score 5 or 6) (Table II).8,13,18
One trial11 did not demonstrate comparability between groups, while all other trials 
conducted a statistical test for comparability between groups. Ten trials had a 2-week 
washout period before administering the study drugs.5–10,12,13,15,18
Antihypertensive Effects
Although the search strategy was designed to identify all related RCTs, the RCTs 
that assessed primary outcomes, including mortality, stroke, coronary heart disease, 
and cardiovascular events, were not identified in the searches. 
When including both low- and high-quality studies, after 4, 6, 8, 32, and 
40 weeks’ treatment, decreases in systolic BP (SBP) and diastolic BP (DBP) were not 
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significantly different in patients receiving (S)-amlodipine 2.5 mg compared with 
racemic amlodipine 5.0 mg (Figures 2–11). When only the high-quality studies 
were included, after 4 weeks’ treatment, the WMD of the SBP and DBP decrease was 
–2.84 (95% CI, –6.42 to 0.74) and –1.71 (95% CI, –3.48 to 0.06), respectively,8
indicating the BP decrease was not significantly different in the 2 groups. Again, 
when only the high-quality studies were considered, after 8 weeks’ treatment, the 
WMD of the SBP and DBP decrease, respectively, was not significantly different in 
the 2 groups (–1.38 [95% CI, –3.62 to 0.86] and –1.33 [95% CI, –2.66 to 0.00])8,18
(Figures 12 and 13). 
To assess the effects of publication bias on the results of the meta-analysis, funnel 
plots of BP at 4 and 8 weeks were made. Asymmetrical plots were obtained, indicat-
ing the presence of reporting bias (Figures 14–17).
Potentially relevant 
studies identified
(N = 229)
Studies excluded after screening of 
titles and abstracts
(n = 172)
Studies excluded (n = 42)
  Nonrandomized controlled trial (21)
  Difference in control (9)
  Difference in cointerventions (6)
  Meta-analysis (1)
  Repeat publication (1)
  Review (1)
  Other reasons (3)
Studies included 
in the analysis
(n = 15)
Studies selected 
for review of full text
(n = 57)
Figure 1.  Identification of eligible randomized controlled trials.
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Table I.  Randomized controlled trials of (S)-amlodipine and racemic amlodipine in the treatment of adults with mild to moderate 
hypertension included in the systematic review and meta-analysis.
Trial
No. of Patients, 
(S)-Amlodipine/
Racemic 
Amlodipine
Washout 
Period
Inclusion 
Criteria
Exclusion 
Criteria Duration Outcomes 
Liu et al5 30/30 4 Weeks (placebo 
for the last 2 wk)
Primary 
hypertension 
Allergy to racemic 
amlodipine, suffered 
cardiac, brain, and 
kidney complications
4 Weeks Blood pressure, 
heart rate, AEs
Cheng et al6 60/60 2 Weeks Mild to 
moderate 
primary 
hypertension
Severe liver or renal 
dysfunction,  
pregnancy, other 
conditions associated 
with poor compliance
5 Weeks Blood pressure, 
AEs
Fang7 140/140 2 Weeks Mild to 
moderate 
primary 
hypertension
Secondary 
hypertension, 
other organic heart 
disease, liver or renal 
dysfunction
40 
Weeks
Blood pressure, 
ultrasound
Hu et al8 110/107 2 Weeks Mild to  
moderate 
primary 
hypertension
Secondary 
hypertension, serious 
cardiac, brain, or renal 
disease
8 Weeks Blood pressure, 
heart rate, AEs
(continued)
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Trial
No. of Patients, 
(S)-Amlodipine/
Racemic 
Amlodipine
Washout 
Period
Inclusion 
Criteria
Exclusion 
Criteria Duration Outcomes 
Zeng et al9 262/262 2 Weeks Mild to 
moderate 
primary 
hypertension
Secondary 
hypertension, valvular 
disease, acute cardiac 
infarction, heart 
dysfunction, diabetes, 
hyperthyroidism, 
cerebral infarction in 
the preceding 2 mo, 
serious liver or renal 
dysfunction
8 Weeks Blood pressure, 
heart rate, AEs
Zhang et al10 30/30 2 Weeks Mild to 
moderate 
primary 
hypertension
Chronic cardiac, liver, 
or renal dysfunction
6 Weeks Endothelial 
function, serum 
cholesterin, AEs
Fang and Feng11 53/53 Discontinue  
anti-ischemic 
drugs, such as 
nitrates, for 1 wk
CHD or 
angina
Pregnant or 
breastfeeding, 
moderate to severe 
anemia, hypertension 
emergency, 
hypersensitivity,  
severe heart block, 
acute cardiac 
infarction
8 Weeks Blood pressure, 
heart rate, ST 
elevation, angina, 
AEs
(continued)
Table I (continued).
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Trial
No. of Patients, 
(S)-Amlodipine/
Racemic 
Amlodipine
Washout 
Period
Inclusion 
Criteria
Exclusion 
Criteria Duration Outcomes 
Yang12 31/26 2 Weeks Hypertension, 
stage 1 or 2
Secondary 
hypertension
8 Weeks Blood pressure, 
AEs
Pathak et al13 97/91 2 Weeks Hypertension, 
stage 1 or 2
Secondary 
hypertension
6 Weeks Blood pressure, 
blood lipids, 
aminotransferases
Li14 40/40 Not mentioned Mild to 
moderate 
primary 
hypertension
Severe liver or renal 
dysfunction, secondary 
hypertension, 
pregnancy, poor 
compliance
5 Weeks Ratio of patients 
with normalized 
blood pressure, 
AEs
Yang et al15 30/30 2 Weeks Mild to 
moderate 
primary 
hypertension
Severe liver and 
renal dysfunction, 
acute myocardial 
infarction, cardiac 
insufficiency, diabetes, 
hyperthyroidism, 
secondary 
hypertension
8 Weeks Blood pressure
Zhang16 36/36 Medication 
for the first 
time or using 
antihypertensives 
other than CCBs 
Mild to 
moderate 
primary 
hypertension 
Severe cardiac, brain, 
or renal complications
8 Weeks Blood pressure, 
heart rate, AEs
(continued)
Table I (continued).
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Trial
No. of Patients, 
(S)-Amlodipine/
Racemic 
Amlodipine
Washout 
Period
Inclusion 
Criteria
Exclusion 
Criteria Duration Outcomes 
Gao and Zhou17 47/47 Not using a CCB 
for ≥8 wk or 
medication for 
the first time
Primary 
hypertension
Secondary 
hypertension,  
diabetes, cardiac 
insufficiency, and renal 
or liver dysfunction
32 
Weeks
Blood pressure, 
left ventricular 
wall thickness, 
carotid artery wall 
thickness
Kim et al18 63/61 2 Weeks Primary 
hypertension
Secondary 
hypertension; 
angina pectoris, 
myocardial infarction, 
cerebrovascular 
disease, or clinically 
significant arrhythmia
8 Weeks Blood pressure, 
heart rate, AEs
Zhu et al19 22/22 1 Week Primary 
hypertension
Serious cardiac, 
cerebral, kidney, 
digestive, respiratory, 
or blood disease; 
malignant tumor; 
history of drug allergy; 
pregnancy or breast 
feeding; surgery within 
2 wk
8 Weeks Blood pressure, 
AEs
AEs = adverse events; CHD = coronary heart disease; CCB = calcium channel blocker.
Table I (continued).
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Changes in Heart Rate
When low- and high-quality trials were considered, meta-analysis of 4 trials5,8,9,16
showed that, after 4 weeks’ treatment, (S)-amlodipine was associated with a signifi-
cantly smaller change in heart rate than with racemic amlodipine (WMD, –0.99; 95% 
CI, –1.70 to –0.28). Meta-analysis of 4 trials8,11,16,18 found that after 8 weeks’ treat-
ment, changes in heart rate were not significantly different in the 2 treatment groups 
(WMD, –0.10; 95% CI, –1.36 to 1.17) (Figures 18 and 19). When only the high-
quality study was included, after 4 and 8 weeks’ treatment, the WMD of heart rate 
change was –0.82 (95% CI, –2.94 to 1.30)8 and –0.87 (95% CI, –2.53 to 0.79),8,18
respectively, indicating the heart rate changes were not significantly different in the 
2 groups.
Adverse-Event Rates
AEs were reported in 13 studies (both low and high quality).5–12,14–16,18,19 The RD 
of the number of patients who experienced AEs with (S)-amlodipine and racemic am-
lodipine was –0.04 (95% CI, –0.06 to –0.02) (Figure 20). When only high-quality 
studies8,18 were included, no difference was found between the 2 formulations in 
the number of patients who experienced AEs (RD, –0.04; 95% CI, –0.10 to 0.02). 
Table II.  Quality of studies included in the systematic review and meta-analysis based 
on the modified Jadad Scale* scores.4
 Allocation Blinding  Total 
Study Randomization Concealment Method Withdrawals Score
Liu et al5 1 0 1 0 2
Cheng et al6 1 0 0 0 1
Fang7 1 0 1 1 3
Hu et al8 1 1 2 1 5
Zeng et al9 1 0 0 0 1
Zhang et al10 2 0 0 1 3
Fang and Feng11 1 0 0 0 1
Yang12 1 0 0 0 1
Pathak et al13 1 1 2 1 5
Li14 1 0 0 1 2
Yang et al15 1 0 0 0 1
Zhang16 1 1 0 1 3
Gao and Zhou17 1 1 0 0 2
Kim et al18 2 1 2 1 6
Zhu et al19 1 1 0 1 3
* Jadad scale: sequence generation—appropriate = 2 points, unclear = 1 point, and inappropriate = 
0 points; allocation concealment—appropriate = 2 points, unclear = 1 point, and inappropriate = 0 points; 
blinding method—appropriate = 2 points, unclear = 1 point, and inappropriate = 0 points; withdrawal 
and exit—described = 1 point and not described = 0 points.
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        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Liu et al5 –20.20 14.21 30 –20.10 14.38 30 5.3% –0.10 (–7.33 to 7.13) 2001
Hu et al8 –15.90 14.45 110 –13.06 12.42 107 21.6% –2.84 (–6.42 to 0.74) 2002
Zeng et al9 –15.60 16.35 262 –14.40 19.02 262 30.0% –1.20 (–4.24 to 1.84) 2002
Yang et al15 –20.10 5.61 30 –16.20 7.34 30 25.3% –3.90 (–7.21 to –0.59) 2006
Zhang16 –26.64 11.86 36 –25.10 10.93 36 10.0% –1.54 (–6.81 to 3.73) 2006
Zhu et al19 –22.66 10.10 22 –23.96 10.06 22 7.8% 1.30 (–4.66 to 7.26) 2008
Total (95% CI)   490   487  –2.02 (–3.68 to –0.35)
Heterogeneity: χ2 = 3.22, df = 5 (P = 0.67); I2 = 0%
Test for overall effect: z = 2.38 (P = 0.02)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 2.  Forest plot illustrating systolic blood pressure after 4 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Random, 95% CI Year  IV, Random, 95% CI
Liu et al5 –11.70 11.42 30 –11.60 11.31 30 11.6% –0.10 (–5.85 to 5.65) 2001
Hu et al8 –13.14 7.26 110 –11.43 5.97 107 18.7% –1.71 (–3.48 to 0.06) 2002
Zeng et al9 –14.60 9.03 262 –7.40 9.40 262 18.9% –7.20 (–8.78 to –5.62) 2002
Yang et al15 –4.40 5.35 30 –4.40 5.35 30 17.2% 0.00 (–2.71 to 2.71) 2006
Zhang16 –12.60 6.14 36 –12.80 5.10 36 17.4% 0.20 (–2.41 to 2.81) 2006
Zhu et al19 –12.04 5.46 22 –11.97 5.39 22 16.3% –0.07 (–3.28 to 3.14) 2008
Total (95% CI)   490   487  –1.67 (–4.68 to 1.34)
Heterogeneity: τ2 = 11.85, χ2 = 43.94, df = 5 (P < 0.001); I2 = 89%
Test for overall effect: z = 1.09 (P = 0.28)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 3.  Forest plot illustrating diastolic blood pressure after 4 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
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        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Pathak et al13 –19.88 9.60 97 –19.24 9.20 91 83.4% –0.64 (–3.33 to 2.05) 2004
Zhu et al19 –23.83 9.96 22 –25.31 10.43 22 16.6% 1.48 (–4.55 to 7.51) 2008
Total (95% CI)   119   113  –0.29 (–2.74 to 2.17)
Heterogeneity: χ2 = 0.40, df = 1 (P = 0.53); I2 = 0%
Test for overall effect: z = 0.23 (P = 0.82)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 4.  Forest plot illustrating systolic blood pressure after 6 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Pathak et al13 –14.32 6.2 97 –13.05 6.20 91 77.6% –1.27 (–3.04 to 0.50) 2004
Zhu et al19 –14.94 5.6 22 –15.13 5.57 22 22.4% 0.19 (–3.11 to 3.49) 2008
Total (95% CI)   119   113  –0.94 (–2.51 to 0.62)
Heterogeneity: τ2 = 0.00; χ2 = 0.58, df = 1 (P = 0.45); I2 = 0%
Test for overall effect: z = 1.18 (P = 0.24)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 5.  Forest plot illustrating diastolic blood pressure after 6 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
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        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Random, 95% CI Year  IV, Random, 95% CI
Hu et al8 –20.76 13.07 110 –17.61 8.53 107 14.6% –3.15 (–6.08 to –0.22) 2002
Zeng et al9 –17.10 16.72 262 –16.80 19.34 262 14.2% –0.30 (–3.40 to 2.80) 2002
Fang and 
  Feng11 –31.00 7.65 53 –28.00 8.51 53 14.2% –3.00 (–6.08 to 0.08) 2004
Yang12 –24.06 12.42 31 –25.21 12.38 26 6.9% 1.15 (–5.31 to 7.61) 2004
Yang et al15 –21.60 6.08 30 –13.70 7.42 30 13.2% –7.90 (–11.33 to –4.47) 2006
Zhang16 –32.60 5.51 36 –30.30 6.42 36 15.1% –2.30 (–5.06 to 0.46) 2006
Kim et al18 –16.70 10.30 63 –17.80 9.40 61 13.1% 1.10 (–2.37 to 4.57) 2008
Zhu et al19 –24.76 9.29 22 –26.49 9.05 22 8.6% 1.73 (–3.69 to 7.15) 2008
Total (95% CI)   607   597  –1.95 (–4.03 to 0.13)
Heterogeneity: τ2 = 5.47; χ2 = 19.24, df = 7 (P = 0.007); I2 = 64%
Test for overall effect: z = 1.84 (P = 0.07)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 6.  Forest plot illustrating systolic blood pressure after 8 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
CTR_V71_N1
Liu 7/24
jh 2/1/10
cws 2/9/10
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Hu et al8 –15.97 6.90 110 –13.68 6.00 107 19.8% –2.29 (–4.01 to –0.57) 2002
Zeng et al9 –15.10 9.03 262 –13.40 8.40 262 26.2% –1.70 (–3.19 to –0.21) 2002
Fang and 
  Feng11 –23.00 9.62 53 –24.00 7.70 53 5.3% 1.00 (–2.32 to 4.32) 2004
Yang12 –13.60 6.80 31 –13.30 6.60 26 4.8% –0.30 (–3.79 to 3.19) 2004
Yang et al15 –13.70 4.72 30 –13.30 6.59 30 6.9% –0.40 (–3.30 to 2.50) 2006
Zhang16 –16.33 3.98 36 –12.69 3.80 36 18.1% –3.64 (–5.44 to –1.84) 2006
Kim et al18 –12.00 5.70 63 –12.10 6.20 61 13.3% 0.10 (–2.00 to 2.20) 2008
Zhu et al19 –15.20 5.36 22 –15.99 5.50 22 5.7% 0.79 (–2.42 to 4.00) 2008
Total (95% CI)   607   597  –1.49 (–2.25 to –0.72)
Heterogeneity: χ2 = 13.70, df = 7 (P = 0.06); I2 = 49%
Test for overall effect: z = 3.81 (P = 0.001)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 7.  Forest plot illustrating diastolic blood pressure after 8 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
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CTR_V71_N1
Liu 8/24
jh 2/1/10
cws 2/9/10
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Gao and 
  Zhou17 –39.00 8.34 47 –40.00 8.63 47 100.0% 1.00 (–2.43 to 4.43) 2007
Total (95% CI)   47   47  1.00 (–2.43 to 4.43)
Heterogeneity: Not applicable
Test for overall effect: z = 0.57 (P = 0.57)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 8.  Forest plot illustrating systolic blood pressure after 32 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
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Liu 9/20
jh 2/1/10
cws 2/9/10
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Gao and 
  Zhou17 –15.00 6.25 47 –16.00 5.56 47 100.0% 1.00 (–1.39 to 3.39) 2007
Total (95% CI)   47   47  1.00 (–1.39 to 3.39)
Heterogeneity: Not applicable
Test for overall effect: z = 0.82 (P = 0.41)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 9.  Forest plot illustrating diastolic blood pressure after 32 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
CTR_V71_N1
Liu 10/20
jh 2/1/10
cws 2/9/10
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Fang7 –29.30 14.10 140 –24.10 10.90 140 100.0% –5.20 (–8.15 to –2.25) 2002
Total (95% CI)   140   140  –5.20 (–8.15 to –2.25)
Heterogeneity: Not applicable
Test for overall effect: z = 3.45 (P < 0.001)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 10.  Forest plot illustrating systolic blood pressure after 40 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
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CTR_V71_N1
Liu 11/24
jh 2/1/10
cws 2/9/10
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Fang7 –22.60 5.70 140 –15.50 6.70 140 100.0% –7.10 (–8.56 to –5.64) 2002
Total (95% CI)   140   140  –7.10 (–8.56 to –5.64)
Heterogeneity: Not applicable
Test for overall effect: z = 9.55 (P < 0.001)       Favors SAML  Favors AML
0 5–5–10 10
AMLSAML
Figure 11.  Forest plot illustrating diastolic blood pressure after 40 weeks’ treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). IV = inverse variance.
CTR_V71_N1
Liu 12/24
jh 2/1/10
cws 2/9/10
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Hu et al8 –20.76 13.07 110 –17.61 8.53 107 58.4% –3.15 (–6.08 to –0.22) 2002
Kim et al18 –16.70 10.30 63 –17.80 9.40 61 41.6% 1.10 (–2.37 to 4.57) 2008
Total (95% CI)   173   168  –1.38 (–3.62 to 0.86)
Heterogeneity: χ2 = 3.37, df = 1 (P = 0.07); I2 = 70%
Test for overall effect: z = 1.21 (P = 0.23)       Favors SAML  Favors AML
0 2–2–4 4
AMLSAML
Figure 12.  Forest plot illustrating systolic blood pressure in the high-quality studies after 8 weeks’ treatment with (S)-amlodipine 
(SAML) versus racemic amlodipine (AML). IV = inverse variance.
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CTR_V71_N1
Liu 13/20
jh 2/1/10
cws 2/9/10
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Hu et al8 –15.97 6.90 110 –13.68 6.00 107 59.8% –2.29 (–4.01 to –0.57) 2002
Kim et al18 –12.00 5.70 63 –12.10 6.20 61 40.2% 0.10 (–2.00 to 2.20) 2008
Total (95% CI)   173   168  –1.33 (–2.66 to 0.00)
Heterogeneity: χ2 = 2.98, df = 1 (P = 0.08); I2 = 66%
Test for overall effect: z = 1.96 (P = 0.05)       Favors SAML  Favors AML
0 2–2–4 4
AMLSAML
Figure 13.  Forest plot illustrating diastolic blood pressure in the high-quality studies after 8 weeks’ treatment with (S)-amlodipine 
(SAML) versus racemic amlodipine (AML). IV = inverse variance.
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Figure 14.  Funnel plot of the meta-analysis of systolic blood pressure after 4 weeks’ 
treatment with (S)-amlodipine versus racemic amlodipine.
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Figure 15.  Funnel plot of the meta-analysis of diastolic blood pressure after 4 weeks’ 
treatment with (S)-amlodipine versus racemic amlodipine.
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Figure 16.  Funnel plot of the meta-analysis of systolic blood pressure after 8 weeks’ 
treatment with (S)-amlodipine versus racemic amlodipine.
CTR_V71_N1
Liu 17/24
cws 2/9
0
0.5
2.0
1.0
1.5
–10 –5 0 5 10
Mean Difference
S
E 
(M
ea
n 
D
iff
er
en
ce
)
Figure 17.  Funnel plot of the meta-analysis of diastolic blood pressure after 8 weeks’ 
treatment with (S)-amlodipine versus racemic amlodipine. 
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CTR_V71_N1
Liu 18/24
jh 2/1/10
cws 2/9/10
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Liu et al5 5.10 6.50 30 3.80 6.80 30 4.5% 1.30 (–2.97 to 4.67) 2001
Hu et al8 –0.85 8.00 110 –0.03 7.90 107 11.3% –0.82 (–2.94 to 1.30) 2002
Zeng et al9 0.00 4.70 262 1.10 4.60 262 79.9% –1.10 (–1.90 to –0.30) 2002
Zhang16 –1.40 5.50 36 0.30 8.90 36 4.3% –1.70 (–5.12 to 1.72) 2006
Total (95% CI)   438   435   –0.99 (–1.70 to –0.28)
Heterogeneity: χ2 = 2.04, df = 3 (P = 0.56); I2 = 0%
Test for overall effect: z = 2.72 (P = 0.007)       Favors SAML  Favors AML
0 2–2–4 4
AMLSAML
Figure 18.  Forest plot illustrating heart rate after 4 weeks’ treatment with (S)-amlodipine (SAML) versus racemic amlodipine 
(AML). IV = inverse variance.
CTR_V71_N1
Liu 19/24
jh 2/1/10
cws 2/9/10
        Mean Difference  Mean Difference
Study Mean SD Total Mean SD  Total Weight IV, Fixed, 95% CI Year  IV, Fixed, 95% CI
Hu et al8 –0.65 7.20 110 –0.03 7.90 107 48.5% –0.62 (–2.63 to 1.39) 2002
Fang and 
  Feng11 0.80 7.10 53 –1.00 7.20 53 26.5% 1.80 (–0.92 to 4.52) 2004
Zhang16 –0.90 4.20 36 –1.00 7.50 36 24.9% 0.10 (–2.71 to 2.91) 2006
Kim et al18 –3.10 7.60 63 –1.70 9.00 61 18.6% –1.40 (–4.34 to 1.54) 2008
Total (95% CI)   262   257   –0.10 (–1.36 to 1.17)
Heterogeneity: χ2 = 2.90, df = 3 (P = 0.41); I2 = 0%
Test for overall effect: z = 0.15 (P = 0.88) 0 2–2–4 4
AMLSAML
Favors SAML  Favors AML
Figure 19.  Forest plot illustrating heart rate after 8 weeks’ treatment with (S)-amlodipine (SAML) versus racemic amlodipine 
(AML). IV = inverse variance.
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CTR_V71_N1
Liu 20/24
cws 2/2/10
cws 2/9/10
      Risk Difference  Risk Difference
Study No. of AEs Total No. of AEs Total Weight M-H, Fixed, 95% CI Year  M-H, Fixed, 95% CI
Liu et al5 2 30 2 30 3.3% 0.00 (–0.13 to 0.13) 2001  
Cheng et al6 4 60 10 60 6.7% –0.10 (–0.21 to 0.01) 2002
Fang7 5 140 8 140 15.5% –0.02 (–0.07 to 0.03) 2002  
Hu et al8 5 110 11 107 12.0% –0.06 (–0.13 to 0.01) 2002
Zeng et al9 6 262 8 262 29.1% –0.01 (–0.04 to 0.02) 2002  
Zhang et al10 5 30 5 30 3.3% 0.00 (–0.19 to 0.19) 2003
Fang and Feng11 0 53 1 53 5.9% –0.02 (–0.07 to 0.03) 2004  
Yang12 1 31 3 26 3.1% –0.08 (–0.22 to 0.05) 2004
Li14 2 40 6 40 4.4% –0.10 (–0.23 to 0.03) 2006  
Yang et al15 2 30 5 30 3.3% –0.10 (–0.26 to 0.06) 2006
Zhang16 1 36 6 36 4.0% –0.14 (–0.27 to –0.01) 2006  
Kim et al18 6 63 7 61 6.9% –0.02 (–0.13 to 0.09) 2008
Zhu et al19 1 22 1 22 2.4% 0.00 (–0.12 to 0.12) 2008
Total (95% CI)  907  897  –0.04 (–0.06 to –0.02)
Total no. of AEs 40  73 
Heterogeneity: χ2 = 11.97, df = 12 (P = 0.45); I2 = 0%
Test for overall effect: z = 3.32 (P < 0.001)
SAML
0 0.1–0.1–0.2 0.2
Favors SAML Favors AML
AML
Figure 20.  Forest plot illustrating the incidence of reports of adverse events (AEs) during treatment with (S)-amlodipine (SAML) 
versus racemic amlodipine (AML). M-H = Mantel-Haenszel.
21
F. Liu et al.
To assess the contribution of different kinds of AEs, the AEs were divided into differ-
ent categories and were compared between (S)-amlodipine and racemic amlodipine. 
Fifteen categories of AEs were identified, among which edema, flushing, and headache 
were the most commonly observed.
Meta-analysis of the low- and high-quality studies that reported AEs5–12,14–16,18,19
indicated that the incidence of edema was significantly lower in the (S)-amlodipine 
group than the racemic amlodipine group (RD, –0.02; 95% CI, –0.03 to 0.00) 
(Figure 21). To assess the effects of publication bias on the results of the meta-analysis, 
a funnel plot of edema was made. An asymmetrical plot was obtained, indicating the 
presence of reporting bias (Figure 22). Moreover, when only high-quality studies8,18
were included, no difference was found between the 2 formulations in the incidence 
of edema (RD, 0.01; 95% CI, –0.02 to 0.03).
Significant differences in increases in aspartate and alanine aminotransferase activi-
ties were found between the (S)-amlodipine and racemic amlodipine treatment groups 
(RD, 0.08; 95% CI, 0.01 to 0.05) (Table III), but this was reported by only 1 trial, 
which was high-quality.18 No differences between the 2 groups were found in the 
other 13 categories of AEs, including headache (RD, 0.00; 95% CI, –0.02 to 0.01) 
(Figure 23) and flushing (RD, 0.01; 95% CI, –0.02 to 0.00) (Figure 24).
Quantified analysis of the seriousness of the AEs was not carried out in any of the 
studies.
DISCUSSION
This review compared the effectiveness and tolerability of (S)-amlodipine 2.5 mg and 
racemic amlodipine 5.0 mg. However, because the majority of the studies included in 
this meta-analysis were of poor quality, the results must be interpreted cautiously.
Although clinical trials that compared (S)-amlodipine and racemic amlodipine 
were collected systematically in this systematic review and meta-analysis, no trials 
that reported cardiovascular outcomes (eg, the incidence of stroke and myocardial 
infarction) were identified. For the secondary outcome measurements (eg, decrease in 
BP), the combined results suggested that (S)-amlodipine 2.5 mg was not significantly 
different from racemic amlodipine 5.0 mg. However, including the findings of the 
low-quality studies reduced the reliability of the results. A conclusion could be drawn 
when only high-quality studies were included in the meta-analysis, but the small 
sample size limited their credibility. As shown by pharmacologic studies, racemic 
amlodipine decreases BP by blocking the L-type calcium tunnel in cell membranes. 
In fact, (S)-amlodipine has this activity but (R)-amlodipine does not. This suggests 
that to achieve the same degree of BP decrease, the dosage of (S)-amlodipine would 
need to be only half that of racemic amlodipine.20
Edema, which was reported in 2% to 11% of patients administered racemic 
amlodipine,21 is a common AE associated with dihydropyridine calcium channel 
blockers. When the findings of the low-quality studies were included, (S)-amlodipine 
2.5 mg was associated with significantly less edema than racemic amlodipine 5.0 mg. 
However, these findings were not considered reliable because of publication bias. 
When only the high-quality studies were considered, no difference in edema was 
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CTR_V71_N1
Liu 21/24
cws 2/1/10
cws 2/9/10
      Risk Difference  Risk Difference
Study No. of AEs Total No. of AEs Total Weight M-H, Fixed, 95% CI Year  M-H, Fixed, 95% CI
Liu et al5 0 30 1 30 3.3% –0.03 (–0.12 to 0.05) 2001  
Cheng et al6 2 60 6 60 6.7% –0.07 (–0.16 to 0.02) 2002
Fang7 1 140 3 140 15.5% –0.01 (–0.04 to 0.01) 2002  
Hu et al8 0 110 1 107 12.0% –0.01 (–0.03 to 0.02) 2002
Zeng et al9 3 262 5 262 29.1% –0.01 (–0.03 to 0.01) 2002  
Zhang et al10 4 30 4 30 3.3% 0.00 (–0.17 to 0.17) 2003
Fang and Feng11 0 53 0 53 5.9% 0.00 (–0.04 to 0.04) 2004  
Yang12 0 31 1 26 3.1% –0.04 (–0.13 to 0.06) 2004
Li14 1 40 2 40 4.4% –0.03 (–0.11 to 0.06) 2006  
Yang et al15 1 30 3 30 3.3% –0.07 (–0.19 to 0.06) 2006
Zhang16 0 36 2 36 4.0% –0.06 (–0.14 to 0.03) 2006  
Kim et al18 2 63 0 61 6.9% 0.03 (–0.02 to 0.08) 2008
Zhu et al19 0 22 1 22 2.4% –0.05 (–0.16 to 0.07) 2008
Total (95% CI)  907  897  –0.02 (–0.03 to 0.00)
Total no. of AEs 14  29 
Heterogeneity: χ2 = 8.41, df = 12 (P = 0.75); I2 = 0%
Test for overall effect: z = 2.20 (P = 0.03)
SAML
0 0.1–0.1–0.2 0.2
Favors SAML Favors AML
AML
Figure 21.  Forest plot illustrating the incidence of reports of edema during treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). AEs = adverse events; M-H = Mantel-Haenszel.
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found between the 2 groups. The small number of cases was also an obstacle to reach-
ing definite conclusions.
Because drug therapy for hypertension needs to be long term, patient compliance 
is an important factor for the successful control of the disease. As reported, patients 
with a high degree of compliance (between 80% and 100%) have a 19% risk of hos-
pitalization compared with 28% in patients with a compliance between 1% and 
19%.22 AEs can considerably influence drug use behavior, as shown by 1 study which 
reported that 7% of the poor compliance was due to AEs.23 Therefore, more studies 
are needed to assess the influence of edema on compliance with (S)-amlodipine and 
racemic amlodipine therapy.
Though studies focused on outcomes are lacking, outcomes are essential in compar-
ing the efficacy of (S)-amlodipine and racemic amlodipine. A major goal of the treat-
ment of hypertension is to reduce cardiovascular events; thus, so cardiovascular out-
comes are key criteria in assessing the effectiveness of antihypertensive drugs. In 
addition, although (R)-amlodipine has not been found to have a protective effect on 
the cardiovascular system and to be associated with AEs, it was found to promote the 
production of nitric oxide (NO) from vessel endothelium.24,25 Because NO has a com-
plicated influence on the cardiovascular system, the role of (R)-amlodipine in hyper-
tension needs further research.
In addition to a lack of outcome assessment, a limitation of the present systematic 
review was the small number of high-quality trials. There were few studies in lan-
guages other than Chinese. Some non-Chinese studies of healthy volunteers were ex-
cluded because they did not comply with the inclusion criteria. However, the studies 
carried out in healthy volunteers found that (S)-amlodipine had comparable pharma-
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Figure 22.  Funnel plot of the meta-analysis of the incidence of edema in patients treated 
with (S)-amlodipine versus racemic amlodipine. RD = risk difference. 
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Table III. Adverse events (AEs) besides edema, headache, and flushing.
  No. of Patients 
  No. of Patients, with AEs, 
 Included (S)-Amlodipine/Racemic (S)-Amlodipine/Racemic 
AE Trials  Amlodipine Amlodipine RD 95% CI P
AST or ALT elevation 118 63/61 5/0 0.08 0.01 to 0.05 0.03
Chest pain 118 63/61 1/1 0.00 –0.04 to 0.04 0.98
Diarrhea 118 63/61 0/1 0.02 –0.06 to 0.03 0.46
Dizziness 35,8,14 180/177 4/4 0.00 –0.03 to 0.03 0.98
Fatigue 16 60/60 1/2 –0.02 –0.07 to 0.04 0.56
Gastrointestinal  27,8 250/247 1/2 0.00 –0.02 to 0.01 0.65
Insomnia 18 110/107 0/1 –0.01 –0.03 to 0.02 0.47
Lymphocytic panniculitis 118 63/61 1/0 0.02 –0.03 to 0.06 0.47
Myalgia 118 63/61 0/1 0.02 –0.06 to 0.03 0.46
Numbness 28,16 142/138 0/2 –0.01 –0.04 to 0.01 0.31
Palpitations 25,8 140/137 2/1 0.01 –0.02 to 0.03 0.62
Rash 118 63/61 0/1 0.02 –0.06 to 0.03 0.46 
RD = risk difference; AST = aspartate aminotransferase; ALT = alanine aminotransferase.
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Liu 23/24
cws 2/1/10
cws 2/9/10
      Risk Difference  Risk Difference
Study No. of AEs Total No. of AEs Total Weight M-H, Fixed, 95% CI Year  M-H, Fixed, 95% CI
Liu et al5 1 30 1 30 3.3% 0.00 (–0.09 to 0.09) 2001  
Cheng et al6 1 60 2 60 6.7% –0.02 (–0.07 to 0.04) 2002
Fang7 2 140 3 140 15.5% –0.01 (–0.04 to 0.02) 2002  
Hu et al8 4 110 5 107 12.0% –0.01 (–0.06 to 0.04) 2002
Zeng et al9 3 262 3 262 29.1% 0.00 (–0.02 to 0.02) 2002  
Zhang et al10 1 30 1 30 3.3% 0.00 (–0.09 to 0.09) 2003
Fang and Feng11 0 53 1 53 5.9% –0.02 (–0.07 to 0.03) 2004  
Yang12 1 31 2 26 3.1% –0.04 (–0.16 to 0.08) 2004
Li14 1 40 1 40 4.4% 0.00 (–0.07 to 0.07) 2006  
Yang et al15 1 30 1 30 3.3% 0.00 (–0.09 to 0.09) 2006
Zhang16 0 36 1 36 4.0% –0.03 (–0.10 to 0.05) 2006  
Kim et al18 2 63 0 63 6.9% 0.03 (–0.02 to 0.08) 2008
Zhu et al19 1 22 1 22 2.4% 0.00 (–0.12 to 0.12) 2008
Total (95% CI)  907  897  0.00 (–0.02 to 0.01)
Total no. of AEs 18  22 
Heterogeneity: χ2 = 3.53, df = 12 (P = 0.99); I2 = 0%
Test for overall effect: z = 0.68 (P = 0.49)
SAML
0 0.1–0.1–0.2 0.2
Favors SAML Favors AML
AML
Figure 23.  Forest plot illustrating the incidence of reports of headache during treatment with (S)-amlodipine (SAML) versus race-
mic amlodipine (AML). AEs = adverse events; M-H = Mantel-Haenszel.
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cws 2/1/10
cws 2/9/10
      Risk Difference  Risk Difference
Study No. of AEs Total No. of AEs Total Weight M-H, Fixed, 95% CI Year  M-H, Fixed, 95% CI
Liu et al5 0 30 0 30 3.4% 0.00 (–0.06 to 0.06) 2001  
Cheng et al6 0 60 2 60 6.8% –0.03 (–0.09 to 0.02) 2002
Fang7 1 140 2 140 15.9% –0.01 (–0.03 to 0.02) 2002  
Hu et al8 0 110 0 107 12.3% 0.00 (–0.02 to 0.02) 2002
Zeng et al9 0 262 0 262 29.8% 0.00 (–0.01 to 0.01) 2002  
Zhang et al10 0 30 0 30 3.4% 0.00 (–0.06 to 0.06) 2003
Fang and Feng11 0 53 0 53 6.0% 0.00 (–0.04 to 0.04) 2004  
Yang12 0 31 0 26 3.2% 0.00 (–0.07 to 0.07) 2004
Li14 0 40 2 40 4.5% –0.05 (–0.13 to 0.03) 2006  
Yang et al15 0 30 1 30 3.4% –0.03 (–0.12 to 0.05) 2006
Zhang16 1 36 2 36 4.1% –0.03 (–0.12 to 0.06) 2006  
Kim et al18 1 63 2 61 7.0% –0.02 (–0.07 to 0.04) 2008
Total (95% CI)  885  875  0.01 (–0.02 to 0.00)
Total no. of AEs 3  11 
Heterogeneity: χ2 = 9.58, df = 11 (P = 0.57); I2 = 0%
Test for overall effect: z = 1.70 (P = 0.09)
SAML
0 0.1–0.1–0.2 0.2
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Figure 24.  Forest plot illustrating the incidence of reports of flushing during treatment with (S)-amlodipine (SAML) versus racemic 
amlodipine (AML). AEs = adverse events; M-H = Mantel-Haenszel.
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cokinetics to racemic amlodipine, and the formulations were not associated with sig-
nificant differences in decreasing BP or safety profiles.26,27 Their conclusions were 
consistent with the findings of our systematic review.
There is a lack of evidence comparing cardiovascular morbidity and mortality as-
sociated with (S)-amlodipine and racemic amlodipine therapy. More long-term, high-
quality RCTs with cardiovascular events as the primary outcome are needed to com-
pare the safety and effectiveness of (S)-amlodipine and racemic amlodipine.
CONCLUSIONS
The majority of the clinical trials comparing (S)-amlodipine and racemic amlodipine 
therapy were low-quality (12/15 [80%]). According to the limited evidence, there 
were no significant differences between (S)-amlodipine 2.5 mg and racemic amlo-
dipine 5.0 mg in controlling BP. When all the trials were considered, (S)-amlodipine 
treatment was associated with significantly less edema than racemic amlodipine; how-
ever, when only high-quality studies were included, no significant difference was 
found between the 2 treatments.
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